Latest News

Morgan Stanley says flu vaccine data is likely to boost Moderna’s stock


Moderna’s phase 2 trial data for its flu vaccine is expected early this year and could push the stock higher.

Dow Jones Newswires: Sanofi, GSK to seek approval for Covid-19 vaccine after positive trial results

Previous article

Need to Know: A bear market is coming, and with it ways to make money not seen in 40 years, says this strategist

Next article

You may also like


Leave a reply

Your email address will not be published.

More in Latest News